Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17662433 | 1.00 | KDM4E (0.35) | KDM4EALDH1A1ITGB3ITGA2BNPSR1 | |
| SCHEMBL11956479 | 1.00 | KDM4E (0.35) | KDM4EALDH1A1ITGB3ITGA2BNPSR1 | |
| SCHEMBL11956480 | 0.95 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL16248528 | 0.95 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL16248523 | 0.95 | KDM4E (0.33) | KDM4EALDH1A1 | |
| SCHEMBL24239548 | 0.89 | OPRK1 (0.33) | KDM4EALDH1A1ITGB3ITGA2B | |
| SCHEMBL19062769 | 0.89 | OPRK1 (0.33) | KDM4EALDH1A1ITGB3ITGA2B | |
| SCHEMBL22800098 | 0.87 | KDM4E (0.35) | KDM4EALDH1A1ITGB3ITGA2BNPSR1 | |
| SCHEMBL22799569 | 0.87 | KDM4E (0.35) | KDM4EALDH1A1ITGB3ITGA2BNPSR1 | |
| SCHEMBL11956481 | 0.87 | CYP2D6 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | STARPHARMA PTY LTD (AU) | 2023-08-24 | — | — | US | disclosed |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | STARPHARMA PTY LTD (AU) | 2023-08-24 | — | — | US | disclosed |
| US-11717574-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2023-08-08 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023057814-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057813-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057812-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| US-20220395525-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2022-12-15 | — | — | US | disclosed |
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | ASTRAZENECA AB (SE) | 2022-09-01 | — | — | US | disclosed |
| US-20200392295-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2020-12-17 | — | — | US | disclosed |
| US-20200069810-A1 | THERAPEUTIC DENDRIMERS | ASTRAZENECA PHARMACEUTICALS LP | 2020-03-05 | — | — | US | disclosed |
| US-10314920-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2019-06-11 | — | — | US | disclosed |
| US-20160194349-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160090595-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-9181549-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9163239-B2 | Compositions and methods for modulating apolipoprotein C-III expression | ISIS PHARMACEUTICALS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9127276-B2 | Conjugated antisense compounds and their use | ISIS PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150126718-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20140343123-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314920-B2 | Therapeutic dendrimers | CD44, ITGAV, FOLR1 | KDM4E 4646/4885ALDH1A1 342/4885ITGB3 21/4885 |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | KDM4E 685/4885ALDH1A1 1047/4885ITGB3 528/4885 |
| US-11717574-B2 | Therapeutic dendrimers | CD44, ITGAV, FOLR1 | KDM4E 4646/4885ALDH1A1 342/4885ITGB3 21/4885 |
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | CD44, FOLH1, SLC17A5 | KDM4E 4248/4885ALDH1A1 342/4885ITGB3 81/4885 |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | SARS1, MMAB, PAM | KDM4E 465/4885ALDH1A1 2061/4885ITGB3 567/4885 |
| US-20200392295-A1 | THERAPEUTIC DENDRIMER | CLTA, DCK, CLTB | KDM4E 2036/4885ALDH1A1 1760/4885ITGB3 709/4885 |
| US-20160194349-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | KDM4E 3205/4885ALDH1A1 2808/4885ITGB3 932/4885 |
| US-11840691-B2 | Compound and application thereof | GALNT6, GALNT3, GALNT14 | KDM4E 3638/4885ALDH1A1 2904/4885ITGB3 1650/4885 |
| US-20220395525-A1 | THERAPEUTIC DENDRIMER | DCK, PAICS, SAMHD1 | KDM4E 1412/4885ALDH1A1 1769/4885ITGB3 122/4885 |
| US-20200069810-A1 | THERAPEUTIC DENDRIMERS | CD44, ITGAV, FOLR1 | KDM4E 4646/4885ALDH1A1 342/4885ITGB3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.